Evidence map›Paper›PMID 34285929›Full record

ArticleOpen forum infectious diseases2021

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing.

Kelly A Johnson, Xin Niu, David V Glidden, Jose R Castillo-Mancilla, Jenna Yager, Samantha MaWhinney, Mary Morrow, Hideaki Okochi, Tim R Cressey, Paul K Drain and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Kelly A JohnsonDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-3333-099X
Xin NiuDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-5888-1419
Jose R Castillo-MancillaUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Jenna YagerUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Samantha MaWhinneyDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.
Mary MorrowDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.
Hideaki OkochiDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Tim R CresseyInstitut de Recherche pour le Développement-PHPT Research Unit, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
Paul K DrainDepartments of Global Health and Medicine, University of Washington, Seattle, Washington, USA.
Monica GandhiDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7025-1994
Peter L AndersonUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Matthew A SpinelliDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USUniversity of Colorado Anschutz Medical Campus · USColorado School of Public Health · USUniversity of Washington · USChiang Mai University · TH

Funding

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
Novel approaches for quantitative assessment of adherenceR01AI122298 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2016 to 2020
$3.4M
Urine tenofovir point-of-care test to identify patients in need of ART adherence supportR01AI152119 · NIAID · STELLENBOSCH UNIVERSITY · PI GANDHI, MONICA, ORRELL, CATHERINE · 2020 to 2024
$1.7M
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)K23MH122286 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPINELLI, MATTHEW A. · 2020 to 2024
$1.0M
A Point-of-Care Assay to Measure Tenofovir for Monitoring PrEP and ART AdherenceR21AI127200 · NIAID · UNIVERSITY OF WASHINGTON · PI DRAIN, PAUL K · 2016 to 2017
$396k
NIAID NIH HHS R01 AI122298NIAID NIH HHS R01 AI143340NIAID NIH HHS R01 AI152119NIAID NIH HHS R21 AI127200NIMH NIH HHS K23 MH122286
6 · The paper itself

Abstract

From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.

Indexed as

directly observed therapypharmacokineticspoint-of-care adherence monitoringtenofovir alafenamidetenofovir disoproxil fumarate

Identifiers

PMID34285929
PMCPMC8286091
OpenAlexW3153805097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.